The role of T helper 25 cells in the immune response to Mycobacterium leprae To the Editor: Although the immunopathogenesis of leprosy has been extensively studied, there has been no investigation of the potential role of T helper 25 (Th25) cells in the disease spectrum. Th25 cells are characterized by the expression of Act1, interleukin 4 (IL-4), IL-13, and IL-25 (also known as IL-17E), which enhance the response of T helper 2 (Th2) cells. [1] [2] [3] To tackle this question, immunohistochemistry was performed in skin samples from 20 patients with untreated leprosy (10 with the tuberculoid form [TT ] and 10 with the lepromatous form [LL] ) by the biotinstreptavidin-peroxidase method using the monoclonal antibodies antieIL-4, antieIL-13, and antieIL-25/IL-17E. Cellular immunostaining results were quantified by 2 independent observers in 5 randomly selected fields visualized under 3400 magnification on a 0.0625-mm 2 grid with 10 3 10 subdivisions using a model 4560006 Axio Imager Z1-Zeiss microscope (Carl Zeiss Ag, Jena, Germany). The unpaired Student t test and Pearson correlation test were applied with a level of 5% (P # .05) considered significant. A significant difference in marker expression was detected between the 2 groups of patients, with a predominance of IL-4 (TT ¼ 10.70 6 2.541 cells per field and LL ¼ 22.80 6 2.251 cells per field; P \ .0001), IL-13 (TT ¼ 10.20 6 2.251 cells per field and LL ¼ 19.00 6 1.764 cells per field; P \ .0001), and IL-25/IL-17E (TT ¼ 15.50 6 3.274 cells per field and LL ¼ 31.20 6 2.098 cells per field; P \ .0001) expression in patients with the LL form of the disease (Fig 1) . This work was approved by the Ethics Committee of the Federal University of Para (Number 72635417.6.0000.5172).
The cytokines IL-4 and IL-13 are known to directly participate in the response of Th2 lymphocytes and in the differentiation of M2 macrophages. 4 Moreover, during establishment of the immunosuppressive environment, the classic actions of IL-4 and IL-13 favor inhibition of the microbicidal response, mainly via M1 macrophages that negatively regulate the production of tumor necrosis factor-, interferon gamma, and induced nitric oxide synthase. In addition to regulating the Th2 cell response, IL-4 and IL-13 modulate the humoral immune response and activation of B cells. 1, 4 IL-25/IL-17E belongs to the IL-17 cytokine family, and unlike the other family members, IL-17A and IL-17F, IL-25/IL-17E reduces the production of Th1 and Th17 cytokines. 5 IL-25/IL-17E also induces the activation of nuclear factor-B; the production of IL-4, IL-5, IL-9, and immunoglobulin E; and mast cell degranulation in the response against extracellular pathogens.
2,3 In the present study, the predominance of IL-25/IL-17E expression in patients with the LL disease form suggests that production of the cytokine may be enhanced to activate the Th2 response as well as M2 macrophages by inducing the expression of IL-4 and IL-13. Our results further corroborate previous observations because IL-25/IL-17E expression was positively correlated with expression of IL-4 (r ¼ 0.7860, P ¼ .0070) and IL-13 (r ¼ 0.8108, P ¼ .0044) and IL-4 and IL-3 expression levels were also significantly correlated (r ¼ 0.8676, P ¼ .0011), indicating that the Th25 lymphocyte response is strongly related to the anti-inflammatory pattern in the LL disease form. Considering that patients with this clinical form of leprosy present a substantial number of lesions, the predominance of the lymphocyte response (Th2 and Th25) and M2 macrophages suggests positive regulation of the mechanisms contributing to immunosuppression or tissue repair.
In summary, analysis of the Th25 cytokines demonstrates the important participation of this profile in the clinical evolution of leprosy in collaboration with the Th2 cytokine profile. Thus, for more severe clinical conditions, induction of the expression of regeneration factors may be an attempt to inhibit the neural lesions that are characteristic of the disease. An exploratory open-label, investigatorinitiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas To the Editor: Although smoothened inhibitors (SIs) are Food and Drug Administration approved for advanced basal cell carcinomas (aBCCs), over 50% of patients do not respond. 1, 2 Preclinical work in models of hedgehog-dependent tumors has revealed the importance of phosphoinositide-3-kinase (PI3K) in promoting SI resistance, [3] [4] [5] [6] with concurrent smoothened and PI3K inhibition delaying SI resistance in medulloblastoma 4 ( Supplemental Fig 1; available at http://www.jaad.org). 1, [3] [4] [5] [6] [7] Due to the lack of good treatment options available to SI-resistant aBCC patients, this open-label, single-arm, proof-ofconcept study of combined hedgehog and PI3K inhibition on aBCCs was explored using sonidegib, an SI, and buparlisib, a pan-PI3K inhibitor.
This study was performed in accordance with Declaration of Helsinki principles. Following institutional review board approval and written informed consent, eligible patients started sonidegib 200 mg and buparlisib 80 mg daily for 28-day cycles. Patients dosed for $2 cycles were evaluable for efficacy at the third cycle and thereafter by using the Response Evaluation Criteria in Solid Tumors version 1.1. All patients receiving $1 dose were evaluated for adverse events (AEs) by using the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03.
By intention-to-treat analysis, 10 patients were evaluable for AEs and 7 were evaluable for response (Consolidated Standards of Reporting Trials, Supplemental Fig 2; available at http://www. jaad.org). Median age at enrollment was 61.0 (range 45-87) years. The median follow-up time was 8 (range 0.5-20) months.
This study was terminated early because of a high incidence of grade 3 AEs, occurring in 50% of the enrolled patients (5 of 10, with a total of 8 events) and consisting of 2 patients with transaminitis, 1 with anxiety, 1 with hyperglycemia, 1 with abdominal pain, 1 with esophagitis, 1 with muscle spasms, and 1 with elevated creatine phosphokinase (Supplemental Table I ; available at http:// www.jaad.org). All AEs were anticipated, attributable to buparlisib ( first 3 of listed AEs) or sonidegib (latter 4 of listed AEs), and resolved upon buparlisib dose reduction or discontinuation of study drugs. Two patients discontinued study drugs due to grade 3 AEs before sufficient time had elapsed to be evaluable for response.
Due to early study termination for toxicity, the sample size for overall response rate determination was limited to 7 patients. The overall response rate was 14.3% (1 of 7 patients), and 71% (5 of 7 patients) experienced stable disease or partial response as the best overall response.
Critically, overall median progression-free survival (PFS) was 13.8 (range 2.0-18.6) months, a duration that exceeded the PFS in long-term studies of single agent vismodegib in SI na€ ıve patients with aBCCs (9.3 months and 12.9 months for metastatic and locally aBCCs, respectively, with combined PFS not reported). 1 The PFS for our study is similar to that found in a recent long-term study of sonidegib monotherapy in SI na€ ıve patients (13.1 and 19.4 months for metastatic and locally aBCC, respectively, again with combined PFS not reported). 2 Our PFS finding is especially promising considering both monotherapy trials 1,2 enrolled patients na€ ıve to SIs, while most patients in our study (5 of 7) had already progressed on SI monotherapy at enrollment, a more challenging population to treat.
Out of 5 patients with pretreatment tissue specimens available for mutation analysis, 1 patient had an activating mutation in PIK3CA, a pathway targeted by buparlisib, and experienced a PFS of 13.2 months (Table I) .
Although the primary findings of this study are the toxicity profile of the pan-PI3K inhibitor buparlisib, we believe that future studies with better tolerated PI3K inhibitors, a class of drugs recently approved by the Food and Drug Administration, 8 are still worthy of careful study, particularly in light of the favorable PFS data in this study, and as salvage therapy for SI resistant aBCCs.
